Jacobs Levy Equity Management, Inc Savara Inc Transaction History

Jacobs Levy Equity Management, Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.04 - $1.34 $1.27 Million - $1.64 Million	-1,220,905 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$1.18 - $1.64 $517,221 - $718,849	438,323 Added 56.01%	1,220,905 $1.69 Million
Q2 2021 Aug 16, 2021	SELL	$1.51 - $2.29 $7,652 - $11,605	-5,068 Reduced 0.64%	782,582 $1.33 Million
Q1 2021 May 17, 2021	BUY	$1.17 - $2.33 $864,642 - $1.72 Million	739,011 Added 1519.38%	787,650 $1.64 Million
Q4 2020 Feb 16, 2021	SELL	$1.0 - $1.47 $164,386 - $241,647	-164,386 Reduced 77.17%	48,639 $56,000
Q3 2020 Nov 16, 2020	SELL	$1.09 - $2.21 $149,325 - $302,761	-136,996 Reduced 39.14%	213,025 $232,000
Q2 2020 Aug 17, 2020	BUY	$1.8 - $3.05 $344,973 - $584,538	191,652 Added 121.02%	350,021 $872,000
Q1 2020 May 15, 2020	SELL	$1.91 - $4.08 $336,767 - $719,377	-176,318 Reduced 52.68%	158,369 $336,000
Q4 2019 Feb 14, 2020	BUY	$0.71 - $4.91 $201,333 - $1.39 Million	283,569 Added 554.73%	334,687 $1.5 Million
Q3 2019 Nov 14, 2019	BUY	$2.16 - $3.2 $110,414 - $163,577	51,118 New	51,118 $135,000

129

151M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $328M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.